NCT04673617 2026-04-03
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics, Inc.
Phase 1/2 Completed
Clinical Trials
12 trialsNCT04426669 2026-02-23
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Intima Bioscience, Inc.
Phase 1/2 Completed
NCT04155710 2025-12-24
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
Iovance Biotherapeutics, Inc.
Phase 1 Completed
NCT05307874 2025-12-24
EVICTION-2
ImCheck Therapeutics
Phase 1/2 Completed
NCT04634435 2025-01-20
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
Biohaven Pharmaceuticals, Inc.
Phase 1 Completed
NCT01671774 2024-11-14
PILOT
Astellas Pharma Inc
Phase 1 Completed
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT00083941 2020-10-19
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
Oxford BioMedica
Phase 2 Completed
NCT00325507 2020-10-19
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
Oxford BioMedica
Phase 2 Completed
NCT01592045 2015-09-23
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
United Therapeutics
Phase 1/2 Completed
NCT00329368 2012-03-09
Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer
Endocyte
Phase 1 Completed
NCT00040586 2007-01-22
Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2
BZL Biologics
Phase 2 Completed